Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). Ryan D. Maynard appointed CFO effective Feb 23, 2026; replaces interim CFO Jeff Sacher.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Ryan D. Maynard appointed CFO effective Feb 23, 2026; replaces interim CFO Jeff Sacher
- Base salary $510,000 with 40% target annual bonus (~$204,000) and $90,000 signing bonus
- Stock option grant for 400,000 shares at market-price strike; 25% vests at 1-year, remaining 75% quarterly over 3 years
- Maynard brings deep biotech CFO experience: Cara Therapeutics, Rigel Pharmaceuticals (16 years), and LetsGetChecked
- Permanent CFO hire signals operational stability: interim leadership transition complete
Item 8.01 · Other Events
- Press release filed Feb 23, 2026 announcing management changes: details in Exhibit 99.1
- Leadership transitions at clinical-stage biotechs can signal strategic pivots or pipeline reprioritization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.